December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

92.77 +2.44 (+2.70%)
Streaming Delayed Price Updated: 10:50 AM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
26 27 Next >
News headline image
Expert Ratings for Incyte ↗
Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Analyst Thinks This Company's Bone Marrow Cancer Treatment Can 'Transform Paradigm' ↗
 
Via Benzinga
News headline image
Incyte to Report Third Quarter Financial Results
From Incyte
Via Business Wire
News headline image
2 Cathie Wood Stocks That Are Beating the Market This Year ↗
One is doing much better than the other year to date, but they both have solid prospects ahead. 
Via The Motley Fool
News headline image
Incyte Names New Member to Its Board of Directors
From Incyte
Via Business Wire
News headline image
MorphoSys' Monjuvi Shows Long-Term Durable Response In Blood Cancer Settings ↗
 
Via Benzinga
News headline image
Incyte Q2 Earnings Beat Estimates But Tightens FY22 Jakafi Sales Guidance ↗
 
Via Benzinga
News headline image
Recap: Incyte Q2 Earnings ↗
  Incyte (NASDAQ:INCY) reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Incyte Acquires Villaris Therapeutics, Deepening Portfolio For Immune-Mediated Dermatologic Diseases ↗
 
Via Benzinga
News headline image
Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody
From Incyte
Via Business Wire
News headline image
Death Cross Looms Over Incyte Investors ↗
If history is any guide, there may be trouble ahead for shares of Incyte (NASDAQ:INCY). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock. 
Via Benzinga
News headline image
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary ↗
 
Via Benzinga
News headline image
Expert Ratings for Incyte ↗
Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Recap Of Friday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Incyte Gets FDA Nod For Hematologic Malignancies Candidate ↗
The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ: INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with... 
Via Benzinga
News headline image
Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
From Incyte
Via Business Wire
News headline image
Data from Incyte’s Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
10 Most Oversold Stocks To Buy In August 2022 ↗
Looking for some oversold stocks to buy? Here's the 10 most oversold on the S&P 500 for August 2022. 
Via Talk Markets
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022 ↗
  
Via Benzinga
News headline image
Incyte Posts Strong Quarter For Cancer Drug; Here's Why Shares Crumbled ↗
Jakafi sales beat and the company raised its guidance. But another drug fell short. 
Via Investor's Business Daily
News headline image
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
News headline image
Biotech Investors: August's Key PDUFA Catalysts You Must Know ↗
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022 ↗
  
Via Benzinga
News headline image
New Indication Approval For Incyte "To Usher New Growth Avenue" ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream for the Treatment of Vitiligo
From Incyte
Via Business Wire
News headline image
The Daily Biotech Pulse: Sesen Bio Stops Lead Assest Development In US, FDA Approves Eton Pharma's Partial Seizures Drug, Bavarian Nordic Inks Multiple Supply Pact For Monkeypox Vaccine ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Incyte to Report Second Quarter Financial Results
From Incyte
Via Business Wire
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.